• PLUS presents at Cannabis Industry Virtual Investor Conference
• Plus Products cracks top-10 edibles product list within two months of expanding into Nevada market
• Company continues expansion by launching into the fast-growing national hemp CBD space

After bringing successful edible cannabis products to market, Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) has steadily increased revenues in the last few years. The company offers the best-selling cannabis product, PLUS UPLIFT Sour Watermelon Gummies, in California, the country’s most competitive state for cannabis companies.

On January 9, the Cannabis Industry Virtual lnvestor Conference was held for an audience of investors, analysts and advisors. The webinar featured presentations from a number of leading players in the cannabis industry, including PLUS. PLUS officials were allotted 30 minutes to present so that investors could receive insight into the dynamic cannabis industry from one of the market’s strongest companies (http://ibn.fm/jL5CG).

In addition, Blake Brennan, PLUS’s head of investor relations, was recently featured on a NetworkNewsAudio interview. In the interview (http://ibn.fm/NU2EB), Brennan noted that PLUS has the “no. 1 gummies brand here in California with the best-selling cannabis product across all categories.” This ranking is according to BDS Analytics, a third-party company that tracks cannabis products and provides accurate insights to consumers.

In the interview, Brennan explained key milestones that the company set out to achieve. “We wanted to build a brand and a product in the largest and most competitive market, make it a winner there, which we’ve done with the best-selling product and the best-selling gummies brand, and then bring it to new markets,” he said. With recent expansion into new markets, Plus Products has taken large leaps forward in this plan.

PLUS launched into the national hemp CBD space, which is forecast to be a market upward of $20 billion dollars by 2022. The full product line is available at PlusProducts.com.

PLUS also began selling its products in Nevada; those products are now available in more than half of the state’s dispensaries. According to Headset, another third-party company that provides real-time insights on cannabis products, PLUS had a top-10 edibles product in Nevada within a month and a half of being on the shelves. Currently the PLUS CBD product line is available in 43 states.

Headquartered in San Mateo, California, PLUS is a hemp and cannabis food company focused on using nature to bring balance to consumers’ lives. PLUS’s mission is to make cannabis safe and approachable, which begins with high-quality products that deliver consistent consumer experiences.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• HTC’s patented Delta Purification™ technology will reuse, recycle, and purify the extraction ethanol used in the cannabinoid extraction process, being designed to reduce waste
• Company is in late-stage negotiations to sign IPGrow™ hemp biomass tolling contracts with producers and hemp biomass providers in the U.S. and Canada for the 2020 hemp growing and production year
• U.S. sales of hemp-based cannabinoid products to reach $22 billion by 2022

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF), a hemp biomass cultivation, extraction, formulation and refining entity, is positioned for rapid market growth through 2020 due to its one of a kind “local to grower” drying-to-biomass storage capability and transportation of dried biomass to its extraction facilities, as well as its patented Delta Purification™ technology. The innovative technology was designed specifically to reduce any cannabidiol waste during the extraction process by recycling, reusing, and purifying the extraction ethanol and re-extracting all waste the purified ethanol yields.

HTC’s proprietary gas, liquid, and biomass extraction systems have been designed for the extraction of gas, liquids, and biomass, and the distillation and purification of ethanol and ethanol-based solvents used for this extraction. The company has spent years developing its ethanol and solvent-based distillation expertise and is now dedicating itself to cannabinoid extraction and refining using hemp biomass tolling agreements.

The company works to expand operations and cement its leading position in the cannabinoid extraction market via new tolling contracts, marketing and distribution agreements, project construction updates, and extraction equipment purchasing. For the 2020 hemp growing and production year, the company will sign IPGrow™ hemp biomass tolling contracts with producers and with hemp biomass providers in the United States and Canada.

A tolling contract between HTC and a 60,000-acre recognized Canadian IPGrow™ hemp biomass producer for the 2020, 2021 and beyond production crop years will take effect in the immediate future. The contract is anticipated to represent production of up to 25,000 acres from a single producer/biomass processor for the 2020 and 2021 and beyond production crop years.

This follows a hemp biomass tolling agreement signed in 2019 for the supply of hemp biomass, from a minimum of 4,200 to a maximum of 5,000 acres of hemp grown in Saskatchewan, using five varieties of Health Canada-approved cultivars as the genetic foundation.

In a move to further expand its operations, HTC acquired California-based Kase Farma Inc., in November 2019. Kase Farma is a high-quality, premium hemp cannabinoid producer who also provides white-label manufacturing for other cannabinoid suppliers, and is widely recognized for its firm engagement to customers, community, and the environment (http://ibn.fm/T1cKu).

As part of its ‘BOOM’ (Build, Own, Operate and Maintain) extraction tolling strategy, the company completed a 19,000-square-foot facility that will house quality assurance testing, extraction and formulation processing, and product development laboratories. The facility is located in Port Lajord, 17 miles from Regina, Saskatchewan. It is currently undergoing interior completion to achieve GMP Euro compliance and will be designed as one of the best-performing, highest-quality extraction and refining facilities in Canada. HTC also finished building its 27,000-square-foot hemp biomass processing and storage facility, which will house extraction-ready biomass.

Overall, HTC Extraction Systems has a highly optimistic outlook when it comes to its extraction market expansion, where it is already a key player. The company expects a wealth of opportunities for growth in the near future, given the rapid expansion of the cannabinoid market as a whole. U.S. sales of hemp-based CBD products are projected to reach $22 billion by 2022, up from $591 million in 2018 (http://ibn.fm/ZoHf8). CBD derivatives such as vapes and edibles are expected to generate $900 million in 2020 (http://ibn.fm/8vNSg). Canada legalized limited forms of recreational cannabis for adult users in the fall of 2018. Sales of these increasingly popular products demonstrate sustainable growth, which will reflect on HTC’s bottom line.

For more information, visit the company’s website at www.HTCExtraction.com

NOTE TO INVESTORS: The latest news and updates relating to HTC are available in the company’s newsroom at http://ibn.fm/HTC

• Unique hemp extract beverage line created via dual infusion clean label process using exclusively natural ingredients with zero chemical additives
• Collaboration with Marijuana Company of America to expand soon to other MCTC drink offerings
• Company files sixth hemp extract delivery patent for single-serving coffee pods containing cannabinoids and a unique dosing system
• MCTC uses strategic agreements, acquisitions, and intellectual property to achieve multiple growing verticals within global cannabis industry

Cannabinoid science innovator MCTC Holdings Inc. (OTC: MCTC) announced the signing of a distribution contract with Marijuana Company of America (OTCQB: MCOA) for the former’s Hemp You Can Feel™ beverage product line. The patent-pending drink line is an organic, ultra-clean label line of CBD powdered drink and hemp extract mixes, including soft beverages and non-alcoholic cocktail mixers, according to a company press release (http://ibn.fm/5ZFiE).

“We are pleased to be providing our products for the HempSMART line from Marijuana Company of America. We share the same beliefs relative to product labeling and we both are proud of this drink line, which is based on organic ingredients and hemp extract infusions containing only natural ingredients,” MCTC CEO Arman Tabatabaei stated in a news release. He added that MCTC also plans to expand the collaboration to other drink offerings to be introduced soon.

MCTC utilizes a unique, two-stage hemp extract infusion process for Hemp You Can Feel™. Unlike most CBD and hemp extract infusions, which use chemicals to balance the mix with hemp extracts, MCTC’s patent-pending line is fully based on natural ingredients.

According to Tabatabaei, his company sees numerous applications for Hemp You Can Feel™ across a wide range of food and beverage applications. “This launch with Marijuana Company of America will be our first, and we are excited to be working with such an innovator in the hemp extract arena on this project,” he added. MCOA specializes in delivering renowned brands through distributors and unique marketing strategies.

Separately, MCTC Holdings also announced the filing of a sixth patent in the field of cannabinoid delivery systems. This patent is for a unique dosing system that makes it possible for any manufacturer of coffee pods to add cannabinoids or other active ingredients to coffee pods with ease (http://ibn.fm/slRs0). An important element of the company’s invention is the ‘Clean Label’ system.

The patent filing outlines a variety of methods and technologies to be used for adding cannabinoids to single-serving coffee pods, Tabatabaei explained. The MCTC system allows any manufacturer of coffee pods to produce CBD or other coffee pods with only a minor modification to their processes. “The patent filing represents growth of our intellectual property to include broader systems for cannabinoid delivery,” the MCTC CEO added. The invention includes the use of Hemp You Can Feel™ technology and other cannabinoid delivery mechanisms, including different nanoparticle and non-nanoparticle technologies.

Tabatabaei also warned about the risk of consuming CBD infusions, underlining that most technologies use extensive processing of extracts and chemicals such as surfactants and emulsifiers in the production processes and that other manufacturers are simply adding little to no active ingredients. The products MCTC intends to deliver to coffee manufacturers will include full certificates of analysis from independent laboratories proving their potency and purity.

MCTC is working with patent counsel to protect various other aspects of its other new technologies. The company has also announced a new research project named THC-V Skinny Cannabinoid Project Varin for THC-V infusions, nanoparticles, and glycosides.

Pending a name change to Cannabis Global, aims to take advantage of opportunities in the cannabis industry while avoiding overcrowded and potentially problematic niches like retail and cultivation. The integrated cannabis business operation and cannabinoid science Innofactor is primarily focused on high-growth and high-margin sub-sectors of the cannabis and hemp industry, including multiple growing verticals in the global cannabis and industrial hemp markets via acquisitions, partnerships and the development of new intellectual property. According to a Research and Markets report, the global industrial hemp market is poised to grow exponentially, from $4.6 billion in 2019 to $26.6 billion by 2025, recording a CAGR of 34% (http://ibn.fm/baahC).

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC

• New board member, audit committee chair brings 35 years of accounting experience, mainly in management
• Prior worked as CFO, controller in several genomics, health companies
• POAI to leverage Prior’s new insights, guidance in the financial space

Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, announced that Pam Prior, CPA, has been appointed to the company’s Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee.

Prior, 57, joins POAI’s Board of Directors with 35 years of experience in accounting, mainly in management as CFO or controller. As the founder and CEO of Priorities Group Inc., a provider of CFO services to small and mid-sized businesses, she has served as a CFO to a number of companies, including Gentris Corp., a private pharmacogenomics company subsequently purchased by Cancer Genetics Inc. Most recently, Prior was CFO at Schiller Grounds Care, a privately held lawn and garden equipment manufacturer.

Other previous CFO experience includes working with companies in the health-industry space such as Global Specimen Solutions, a privately held technology company for specimen and consent management (later purchased by Covance), and multimillion-dollar companies in other industries such as Greatwide Truckload Management, a $300 million subsidiary of a $1 billion privately held logistics company.

“Predictive Oncology is very fortunate to announce that Pam Prior is joining our Board of Directors,” Predictive Oncology CEO Dr. Carl Schwartz stated in a news release (http://ibn.fm/hJEDR). “Pam possesses a strong financial background, including in the genomic and health industry fields. She will chair our audit committee, providing new insights and guidance to our Board and the financial departments of the company. I greatly anticipate working with Pam and experiencing the successful approach she has honed over the years.”

In addition to her background in the health industry, Prior also has experience serving as controller for several publicly traded companies and their subsidiaries, including Tasty Baking Company and PCI Services, a part of publicly held Cardinal Health.

Prior is a licensed CPA in the Commonwealth of Pennsylvania, with an MBA and a bachelor’s degree from the University of Delaware. She also serves as treasurer on the boards of two nonprofit organizations: The Crossing Choir, a professional choir holding two Grammy Awards and seven Grammy nominations, and A Soldier’s Hands, a grassroots organization dedicated to delivering care packages to deployed United States military personnel.

As a highly respected and seasoned finance executive with valuable genomics and health industry experience, Prior joins POAI at a time when the company has announced a significant milestone in its CancerQuest 2020 initiative. The initiative indicates a progression in its proprietary AI-driven predictive model of ovarian cancer, which it expects to commercialize in the first quarter of 2020.

Prior’s engagement in providing new insights and guidance to the board and POAI’s financial departments will position the company to capitalize on its cutting-edge technology that offers an unparalleled predictive tool for pharmaceutical companies and medical researchers, enabling more effective development of new drugs and supporting clinicians in creating individualized therapies for their patients.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• CIIX subsidiary working to expand customer base with new hemp-based CBD products in 2020
• CEO focused on profits in 2020; plans to create strategic B2B, B2C divisions
• CBD Biotech unaffected by changing CBD-product regulations due to company’s focus on hemp-based CBD cosmetics

ChineseInvestors.com Inc. (OTCQB: CIIX) is a financial news media and content platform that provides information to the global Chinese-speaking community. After realizing the multitude of opportunities in the growing cannabis sector, especially concerning China’s nascent CBD market, CIIX has worked to cultivate an attractive lineup of products through its subsidiary CBD Biotech. While cannabis is still highly illegal in China, hemp-based CBD can be legally added to cosmetics. The team at CIIX recognizes the massive potential of the untapped Chinese CBD market.

CIIX has a user base of more than 100,000 people and has been around since 1999. Company CEO Warren Wang recently made an appearance on MoneyTV, during which he spoke about the company’s plans for 2020, many of which involve CBD Biotech. “The key is profit,” Wang stated in the interview (http://ibn.fm/Ub6cJ). “Secondly [we will] expand our market. Thirdly, we are going to divide the company divisions into B2B and B2C.”

Wang outlined plans to advertise via social media platforms such as TikTok in order to increase CIIX’s brand recognition and deepen its market penetration. In China, Wang explains, several different social media platforms have massive followings, as “young generations will use a lot of social media to know the products, know the commentary, and they will buy the products from Ecommerce platforms.”

Wang noted that China’s changing CBD laws can create volatility for CBD companies. However, those laws don’t apply to hemp-based CBD cosmetics, which are fully legal in China, Japan and the United States. Because CIIX is only involved in CBD cosmetics, the company remains unaffected by the changing regulations and is able to operate in a stable environment.

In 2020, CIIX will be launching new CBD cosmetic products, including an anti-aging product formulated to combat wrinkles. By targeting the Chinese-speaking community, CIIX has few competitors and plenty of room to grow. The company maintains its attention on the investment of both the distribution and the research and development of new CBD products.

CIIX is a diverse company driven by educational services and the sales of cosmetics, hemp wine and CBD. CIIX offers its audience of Chinese-speaking investors real-time market commentary, analysis and educational-related services in both traditional and simplified Chinese character language sets.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• In-process quality-control issues present major impediments to scalability, profitability in 3D metal printing
• EV production has begun using 3D printing to manufacture customized parts to overcome the limitations of traditional manufacturing
• SGLB is only known provider of software that addresses issues through real-time, in-process detection of irregularities and error reporting

City expansion fueled by global population growth is creating ever increasing demand for sustainable compact electric vehicles as a means of traversing increasingly complex urban environments. The 3D metal-printing industry is helping to bring these concept vehicles to life through the 3D formation of many requisite parts – from interior consoles, display frames, plug socket fixtures, air vents and lidar screens right down to license plates (http://ibn.fm/hMR75). Quality control remains one of the prime impediments to the entire auto industry to reach scalability and profitability using 3D printing. Sigma Labs Inc. (NASDAQ: SGLB), with its revolutionary software, is the only provider of in-process, quality-assurance software to the global 3D metal-printing industry.

The use of EVs (electric vehicles) is becoming more widespread as communities around the world are moving toward the environmentally friendly option to facilitate in-house company deliveries, provide airport transit and taxi pick-ups, perform parcel collections and navigate supermarkets. However, quality control in 3D metal printing continues to pose serious logjams due to costly and labor-intensive methods that stymy scalability and profitability. SGLB is the go-to provider of quality control software solutions, bringing the requisite quality control needed to eliminate inefficiencies and realize the advantages of the 3D metal-printing process. The company’s innovative solutions promise to save time in the delivery of high-quality, customized precision parts; refine the production process; and save costs, ushering in what many believe to be the fourth industrial revolution in manufacturing (http://ibn.fm/1SEGs).

While on the cusp of an explosive moment for the manufacturing sector, postproduction inspection and rejected output caused by variances in 3D metal printing process hamper consistent quality and impede scalability, creating one of the largest challenges to the industry. Due to the nature of the production process, manufacturers do not know if design specifications are met until the end of the process when parts are inspected using CT scans and other costly techniques.

Sigma Labs’ PrintRite3D solution to the challenge provides real-time error detection using software that reports errors in-process, reduces postproduction inspection times and eliminates rejects, resulting in cost savings, increased production runs and larger profits. Sigma Labs’ innovative software may very well be one of the tools that allows the EV industry and the entire 3D metal printing industry to scale up economically, moving far beyond prototype manufacturing to truly economically viable commercial production.

Sigma Labs provides software that addresses the critical quality control issues in two ways. First, SGLB’s proprietary PrintRite3D® software solution enables real-time, in-process detection of manufacturing irregularities. Second, PrintRite3D involves error reporting that provides operators with critical actionable information enabling them to adjust the process and mitigate any developing anomalies during the production process.

Sigma Labs, with its PrintRite3D® brand, presents a real-time, computer-aided inspection solution that resolves these major roadblocks and costly quality-control challenges, drastically reducing errors made in-process and eliminating costly rejects in the postprocess phase.

Founded in 2010 by a team of Los Alamos National Labs scientists and engineers, SGLB initially focused on advanced metallurgical products for the military ordinance and dental implant industries. Sigma Labs concluded that the 3D metal printing space offered enormous potential to any company that could provide in-process, quality-assurance tools that observe, manage and control manufacturing complexities for reliable production of high-precision, quality metal parts.

SGLB’s products and services are tailored for use in highly demanding, precision-dependent industries such as the EV, aerospace, defense, transportation, oil and gas, and biomedical spaces. The company’s global client base includes 23 RTE installations across 19 different users, including tier-1 OEM enterprises and end users such as Siemens, Honeywell, Pratt & Whitney among many others that are currently evaluating PrintRite3D for use on their production lines.

Sigma Labs aims to position its groundbreaking software as the catalyst that may help propel the 3D metal-printing industry into the fourth industrial revolution in manufacturing.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

• Gateway Innovations Limited’s first project, the $200 million Ghana Cyber City, is set to become West Africa’s premier hub of innovation
• The acquisition brings Xalles Holdings one step closer to its goal of establishing a series of strategic global fintech centers
• Xalles aims to sustain profitability through revenue growth and continued vigilant expense management techniques in 2020

Xalles Holdings Inc. (OTC: XALL), one of the first providers of payment and financial transaction management solutions through proprietary blockchain-based technology, announced it has executed an agreement for the acquisition of Gateway Innovations Limited. This company, which is based in Accra, Ghana, is a major investor in Africa’s fintech and IT market, according to a Xalles Holdings press release (http://ibn.fm/pwId5).

Under the agreement, Gateway will become a wholly owned subsidiary of Xalles. The closing date is February 14, 2020. Gateway will receive restricted shares in Xalles in exchange.

Gateway Innovations develops high impact tech parks in Africa. Its aim is to maximize the productivity of businesses in West Africa by developing “smart city” solutions. The first such project, Ghana Cyber City comprises intelligent leasing workspaces, resources and technological infrastructure to incubate and accelerate new fintech and other ventures, a high-tech campus of business colleges, a top-tier data center, and more.

Ghana Cyber City, worth $200 million upon completion, is being developed on land leased from the University of Ghana. A master plan, site plan, and financing plan have already been drafted. Xalles is bringing its fintech expertise to the project. Within the overall Ghana Cyber City will be the first of its kind Africa Fintech Center.

“We are pleased to announce this acquisition as a step towards establishing a series of strategic global fintech centers and even more pleased that the first of its kind will be based in the high growth market of Ghana in West Africa,” Thomas Nash, CEO of Xalles Holdings, stated in a news release. “I have known and worked with Gateway’s founders since 2006 and the combined skills and experience of the management team plus the unique opportunity this project presents financially will provide a considerable asset and income value to Xalles.”

Xalles is a fintech holding company leveraging blockchain and other technologies for e-commerce, payments, financial reconciliation, and payment auditing solutions. The company actively seeks acquisition targets with strong management teams and business models, large total attainable markets, and lucrative exit opportunities in which to invest and accelerate growth.

Xalles Holdings plans to make cryptocurrency trading and other related services more accessible to clients. Focused on business, consumer, and government-oriented payment and financial reconciliation transactions, the company is building technology that supports payment exchange, audits, and new business models and global opportunities by combining the blockchain decentralized financial ledger platform with the company’s existing, state-of-the-art transaction reconciliation system design.

Xalles was among the first providers of payment and financial transaction management solutions through proprietary blockchain-based X2X technology. One of these solutions is the IFS (Investment and Financing System), which provides links to Xalles’ Financial Transaction Reconciliation (FTR) solution, supports complex investment structures, assists international investment corporations, and more.

In addition, the company will launch new services card and mobile payment and rewards systems, and will expand the technology offerings for referral marketing and e-commerce engines – a move expected to bring significant opportunities given the rise of mobile payment systems and the continued expansion of business-to-business e-commerce. According to a Business Insider Intelligence report, mobile payment systems are becoming more and more popular, with consumers becoming less dependent on fiat currencies as a result. Non-cash transactions are expected to surpass one trillion by 2023 (http://ibn.fm/rJBq2).

For more information, visit the company’s website at www.Xalles.com

NOTE TO INVESTORS: The latest news and updates relating to XALL are available in the company’s newsroom at http://ibn.fm/XALL

• Leading private equity firms 1315 Capital and Ampersand Capital Partners’ recent investment agreement with Interpace signal a “clear vote of confidence”
• Company’s business units, Interpace Diagnostics and Interpace Pharma Solutions, support the biotech and pharmaceutical sectors as they seek to improve early cancer diagnosis and promote increasingly effective therapies
• Life sciences industry forecast to reach $33.2 billion by 2024, experiencing an 11.5% CAGR over 5-year period

Interpace Biosciences (NASDAQ: IDXG), an evolving leader in the life sciences industry, recently entered into a $20 million investment agreement with two leading private equity firms investing in laboratory services (http://ibn.fm/G8cUU). The Series B Preferred stock investment consisting of $19 million and $1 million from 1315 Capital and Ampersand Capital Partners, respectively, will be a boon to IDXG’s growing power in an industry anticipated to reach $33.2 billion by 2024 – an increase from its $19.3 billion in 2019. The life sciences industry is forecast to experience a CAGR of 11.5% over the period (http://ibn.fm/H1lmI).

“We believe 1315 Capital will be, and Ampersand [a current investor] will continue to be, great partners for Interpace,” Interpace president and CEO Jack Stover stated in a news release. “This is a clear vote of confidence in Interpace and its diagnostic and pharma solutions businesses.”

In addition to the investment agreement, Interpace also announced its intention to effect a one-for-ten reverse stock split effective coincident with the former’s closing. The reverse stock split is meant to satisfy the Nasdaq Capital Market’s minimum bid price requirement by increasing the per share trading price of IDXG’s common stock. “We believe this proposed change in capital structure can benefit our stockholders and make our stock more attractive to institutional and other investors,” Stover noted.

Having assisted physicians in the diagnosis and treatment of over 75,000 patients, Interpace Biosciences has made contributions to some of the pharmaceutical and biotech industry’s most critical clinical trials (http://ibn.fm/ENyPi). Its business arms, Interpace Diagnostics™ and Interpace Pharma Solutions™, support the biomedical and oncological industries by empowering clinicians with complex molecular analysis data. This data helps enhance the efficacy of early cancer diagnosis and treatment, as well as supporting the development of targeted therapeutics.

Business unit Interpace Diagnostics™, focused on “resolving diagnostic uncertainty,” offers evidence-based, clinically beneficial molecular diagnostic tests and pathology services (http://ibn.fm/T04KG). Its offerings include reputable tests like PancraGen®, ThyGeNext®, ThyraMir®, RespriDX® and BarreGen®. The company’s tests assist in risk stratification of patient samples for a multitude of cancers, including thyroid, pancreatic and lung, among others. Results gleaned from these tests are used by physicians to make better, more effective treatment decisions that more accurately target each individual patient – determining whether patients are better suited for surgery or active surveillance. These recommendations have the potential to help health care professionals differentiate between potentially malignant cells and benign ones, thus saving patients from risky, expensive surgeries that are frequently unnecessary.

Alternatively, IDXG’s Interpace Pharma Solutions™ business unit works hand-in-glove with biopharmaceutical companies by providing lab testing, data management, project management and biorepository services (http://ibn.fm/joRK6). By utilizing Interpace Pharma Solutions’ scientific, medical and expert knowledge, biopharma and diagnostic clients are able to effectively integrate pharmacogenomics – the study of how genes affect a person’s response to drugs – into their drug development and clinical trial programs. Interpace Pharma Solutions’ platform generates logistical reports comprised of biomarker analysis, anatomic pathology, cytogenetics and customized molecular technologies (http://ibn.fm/619vG). As medicine personalized through the lens of genetics was recently referenced as one of the top trends in the life sciences industry (http://ibn.fm/KGwPA), Interpace Biosciences appears well-positioned to stay abreast of the dynamic industry and is an attractive option for pharmaceutical and biotech companies conducting or aiding in oncology-focused clinical trials.

Globally, the molecular diagnostics market is estimated to experience a CAGR of 8.7% during the forecast period from 2018 to 2024 (http://ibn.fm/6hNeA). With a comprehensive testing portfolio, Interpace Biosciences presents a convincing opportunity for investors looking to benefit from the global community’s growing reliance on personalized medicine.

For more information, visit the company’s website at www.Interpace.com

• No Borders, Inc. is a technological solutions innovator dedicated to a variety of market verticals, including the buzzworthy hemp CBD products and blockchain technology sectors
• No Borders cannabidiol (CBD) products can help people addicted to painkillers or suffering from poor sleep to improve their general wellbeing
• Blockchain applications developed through No Borders’ tech labs can help ensure the quality and legality of CBD products from test to shelf, and blockchain’s worth is becoming more evident as government agencies experiment with its data-tracking capabilities

Trust and wellness provider No Borders Inc. (OTC: NBDR) inspires confidence through its diverse approach to market building, living up to its name by extending its reach to a variety of explosive growth verticals. Two of those sectors are hemp-based cannabis products and blockchain security applications, which can work together to symbiotically help consumers improve their general well-being.

Blockchain has been gaining attention for well over a decade as a device for building confidence in online transactions. Its core principle is that a finalized record of every aspect of a transaction can be created and shared among all participants in the transaction as the events occur, thereby virtually eliminating the likelihood of fraud occurring through irreconcilable alteration of a digital record.

The secure microcosm-building capacity of blockchain has gained popularity in digital currency transactions across all borders – creating the potential for a ‘No Borders’ world – and is increasingly being touted as a means of ensuring consumable products’ safety and quality. That’s where its use in the hemp derivatives market comes in – popular extracts such as cannabidiol (CBD) can be scary for consumers to try and No Borders internally built, owned and deployed blockchain PAAS, CBD LabChain provides consumers with a tangible trust layer with entries from lab tests along the road to market showcasing the product’s established quality, efficacy and THC Free compliance.

Blockchain tracking of CBD products even creates the potential of the government someday being able to establish affordable scientific testing of extracts’ qualities for the purpose of building a reliability standard the Food and Drug Administration (FDA) can turn to in questions of legalization at a federal level.

Blockchain applications began as something of an underground alternative to official processes and procedures, but government administrations are including blockchain capabilities in their thinking more and more often. An example of the sea change is shown in the announcement that the U.S. Treasury is testing a blockchain-based subsidy process designed to “make the allocation and use of funding more efficient through traceable data storage,” according to a recent report by Medium (http://ibn.fm/4ex2Y).

The market’s potential to use blockchain in its production pipelines may help it prevent disasters such as the deadly Tylenol consumer poisonings nearly 40 years ago that resulted from an unknown assailant tampering with store products (http://ibn.fm/flMGc).

Blockchain tracking of retail products may also help ensure consumers about the quality of CBD products and thereby avoid costly problems associated with products that don’t adhere to desired standards. The Department of Defense has a zero-tolerance policy for service members who illegally or improperly use drugs, for example, which includes substances such as CBD oil.

“Even if CBD extract contains 0.3 percent or less of THC, service members put themselves at risk if they consume these products without being prescribed an [Food and Drug Administration]-approved product by a medical professional,” Air Force Capt. Marcus Walker, 436th Airlift Wing Assistant Staff Judge Advocate, told the Defense Visual Information Distribution Service (http://ibn.fm/3J1fz).

“Products may contain more THC than expected and have the potential to cause a positive urine drug test and intoxication, which may affect military readiness. These products may also be adulterated with other active components, like synthetic cannabinoids, which may lead to intoxication and accidents,” Dr. Erin Karschner, Armed Forces Medical Examiner System forensic toxicologist added.

No Borders CEO Joseph Snyder is bullish about the benefits of CBD, however.

“I was introduced to CBD after spending over four years on prescription opioids for back to back shoulder surgeries, within hours I knew there was an impact and within days I knew I didn’t need the poison opioids anymore,” Snyder stated in an email to NetworkNewsWire about his recovery from a prior painkiller addiction that resulted from numerous injuries and surgeries.

“I knew we as a company and I as a human, needed to share CBD with the world,” he added. “So began No Borders Naturals, now proudly secured and certified on blockchain with our proprietary CBD LabChain.”

A separate email touts CBD’s effectiveness in helping people to overcome restless sleep patterns. Poor sleep is linked to a lack of energy and potentially to poor health (http://ibn.fm/k2YEi).

“While researchers still don’t fully understand why CBD helps with sleep, there is a lot of convincing research out there,” the email states. “Another reason that CBD can be so helpful for sleep issues is that it can reduce discomfort caused by all sorts of conditions. Those who have arthritis or muscle aches can find it difficult to get a good night’s sleep on a regular basis.”

For more information, visit the company’s website at www.NBDR.co

NOTE TO INVESTORS: The latest news and updates relating to NBDR are available in the company’s newsroom at http://ibn.fm/NBDR

• SGLB delivers solutions to additive manufacturing challenges with its proprietary PrintRite 3D technology
• Sigma Labs allows companies to build, qualify, and certify parts more quickly and at lower cost
• Before Sigma, no quality metric existed for melt pool monitoring, in situ monitoring, or process quality control that provided in process alerts and solutions

As additive manufacturing – or 3D metal printing – gains traction in the manufacturing world, the problems with the technology have hampered production and stymied large-scale uptake. Sigma Labs Inc. (NASDAQ: SGLB), a leading producer of quality-assurance software for the commercial 3D-printing industry, is committed to providing answers to those problems in the latest version of its proprietary technology.

“For some engineers, 3D printing may be coming on in an unwelcome rush,” stated a recent Engineering.com article, titled ‘7 Issues to Look Out for in Metal 3D Printing’ (http://ibn.fm/WP70j). “Avoiding issues in metal AM still requires a lot of process knowledge and trial and error,” the article states, denoting how critical it is for operators to monitor processes in real-time—a problem for which SGLB’s PrintRite 3D software offers a solution.

In its own article (http://ibn.fm/whFCl), ‘What Is Metal Additive Manufacturing’, Sigma Labs also acknowledges that “the large-scale adoption of direct 3D metal additive manufacturing faces quality and reliability challenges.” Those challenges are outlined in the article as follows:

• The machines and processes are inherently variable – machine to machine and within machine – causing variation in manufacturing and production consistency.
• The build process itself has many adjustable inputs that directly affect the ability to create a part and its final quality.
• The industry has few design rules, monitoring methods or standards for finished products.
• There is difficulty ensuring consistent, repeatable quality for final production parts.

In what it calls the “Sigma Solution,” Sigma Labs argues that its IPQA™ technology accurately monitors the quality and reliability of additive manufactured parts by ensuring consistent quality control during the manufacturing process. Until now, optical monitoring systems have recorded the manufacturing process but have been unable to deliver actionable in-process information to enable the rescue of parts straying out of specification. Additionally, parts could only be fully quality inspected post-production in costly and time-consuming processes and only after the mistakes were made. Sigma’s real-time melt pool analytics software frees manufacturers to build, qualify and certify parts more quickly and at a much lower cost.

Sigma’s proprietary software reduces the traditional post-production quality assurance inspection process for additive manufacturing; helps ensure the quality of each part; dramatically reduces costs and labor associated with the current approach to certifying AM part quality by “seeing” and analyzing the structure of a 3D-printed part during production; and allows for correction during the manufacturing process.

Sigma Labs was founded in 2010 and has become the go-to, 3D-printing expert for real-time, computer-aided inspection (CAI) solutions. Founded by experts from scientific disciplines that include metallurgy, physics, signal processing, mechanical engineering, optics, software AI and ML, data analytics and visualization, the company has already established credibility within highly demanding industries such as aerospace, defense, biomedicine and transportation. Sigma Labs’ revolutionary technology is set to unleash the powerful forces of 3D metal printing, changing the face of the industry by increasing reliability, lowering quality control costs and enabling serial manufacturing.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB